ONKURE THERAPEUTICS, INC. STOCK OPTION AGREEMENT NOTICE OF STOCK OPTION GRANTStock Option Agreement • August 19th, 2024 • Reneo Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
Unless otherwise defined herein, each capitalized term used in this Stock Option Agreement, which includes the Notice of Stock Option Grant (the “Notice of Grant”), the Terms and Conditions of Stock Option Grant, attached hereto as Exhibit A, the Exercise Notice, attached hereto as Exhibit B, and all other exhibits, appendices, and addenda attached hereto (the “Option Agreement”), will have the meaning given such term in the OnKure Therapeutics, Inc. (the “Company”) 2024 Equity Incentive Plan (the “Plan”).
ONKURE THERAPEUTICS, INC. OUTSIDE DIRECTOR COMPENSATION POLICYOutside Director Compensation Policy • August 19th, 2024 • Reneo Pharmaceuticals, Inc. • Pharmaceutical preparations
Reneo Pharmaceuticals, Inc. (which, as of the Closing, as defined in that certain Agreement and Plan of Merger entered into by and among Reneo Pharmaceuticals, Inc., Radiate Merger Sub I, Inc., Radiate Merger Sub II, LLC, and OnKure, Inc., dated May 10, 2024, as may be amended from time to time (the “Merger Agreement”) is expected to operate under the name, “OnKure Therapeutics, Inc.”) (the “Company”) believes that the granting of equity and cash compensation to members of the Company’s Board of Directors (the “Board,” and members of the Board, “Directors”) who are not employees represents an effective tool to attract, retain and reward such Directors. Unless otherwise defined herein, capitalized terms used in this Policy will have the meaning given such term in the Company’s 2024 Equity Incentive Plan, as amended from time to time, or if such plan no longer is in use at the time of the grant of an equity award, the meaning given such term or similar term in the equity plan then in pla
ONKURE, INC. EMPLOYMENT AGREEMENTEmployment Agreement • August 19th, 2024 • Reneo Pharmaceuticals, Inc. • Pharmaceutical preparations • Colorado
This Employment Agreement (the “Agreement”) is entered into as of the Effective Date (as defined below) by and among OnKure, Inc. (the “Company”), Reneo Pharmaceuticals, Inc., (which following the Effective Date (as defined below), will be OnKure Therapeutics, Inc.) (“OnKure”) and [NAME] (“Executive”). Certain capitalized terms used in this Agreement are defined in Section 11.
